# Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

> **NCT03596970** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** TAC withdrawal
- **DRUG:** Everolimus with reduced TAC

## Key facts

- **NCT ID:** NCT03596970
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-09
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596970, "Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03596970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*